

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Lenacapavir for preventing HIV-1 in adults and young people [ID6495]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was noted that HIV disproportionately affects people of Black African, Black Caribbean and other minority ethnic backgrounds. It was also noted that HIV is more prevalent in people of certain sexual orientation, such as gay or bisexual men. Some groups who are socioeconomically disadvantaged, such as homeless people and people who inject drugs, may also be disproportionately affected by HIV.

While Pre-Exposure Prophylaxis (PrEP) is a key component of HIV prevention, some people may face barriers to accessing oral PrEP due to stigma, discrimination or lack of awareness of PrEP. Oral PrEP may also be unsuitable for some people. Stakeholders highlighted inequity in access to and uptake of oral PrEP across population groups, including but not limited to trans, non-binary and gender diverse populations, minority ethnic communities and socioeconomically disadvantaged groups.

Lenacapavir will need to be administered in a healthcare setting. This may make it difficult for people with a disability or caring responsibilities to access lenacapavir as they might find it challenging to visit a healthcare setting in person.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider any relevant equalities issues in its deliberations.

Issues related to differences in prevalence or incidence of a disease cannot be addressed in this technology appraisal.

If evidence allows, the committee may consider whether there are any subgroups for whom the clinical and cost-effectiveness of lenacapavir is expected to be different. The committee will be mindful of equality considerations when assessing subgroups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the scope. The committee will consider all relevant potential equality issues during the appraisal process.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were added.

Approved by Associate Director (name): Ian Watson

Date: 15 May 2025